Basel — March 18, 2013
Alcon, the global leader in eye care and a division of Novartis, announces that the European Commission has approved Jetrea® intravitreal injection (ocriplasmin) in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. VMT is often responsible for progressive sight-threatening symptoms and irreversible vision loss, and is estimated to affect between 250,000 to 300,000 people in Europe alone.
The pivotal studies, published in the New England Journal of Medicine, showed that patients who were treated with Jetrea successfully achieved resolution of VMT and closure of macular holes as compared to placebo at day 28.
This treatment will avoid surgery in many cases and will be available in our centre shortly.